MANAGEMENT OF RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CARCINOMA (RAI-R DTC)

RACP

This case study-based activity will take approximately one hour to complete and will focus on patient selection for, and practical aspects of, tyrosine kinase inhibitors in RAI-R DTC.

Learning outcomes

By the end of this course, participants should be able to:

  • Outline the importance of identifying patients with radioiodine-refractory differentiated thyroid carcinoma.
  • Discuss the potential benefits of initiating tyrosine kinase inhibitors.
  • Summarise the practical aspects of using tyrosine kinase inhibitors, including management of possible side effects.
RACP

This education has been designed for the RACP CPD Program for the 2023-25 triennium. Upon completion of this activity you may claim 1 hour of Category 1 Educational Activity learning in the RACP’s MyCPD program.

Other healthcare professionals can still enrol and complete this course. You will receive a certificate upon completion.

START LEARNING

If you do not already have an account with Arterial Education, you will be required to create one. This verifies that you are a healthcare professional and allows you to log your learning activities.